Esperion Therapeutics Merger Clears HSR Hurdle, Stockholder Vote Set for July 8
ESPR has more than doubled off its 52-week low of $0.949.
Summary
The Hart-Scott-Rodino (HSR) waiting period for Esperion Therapeutics' acquisition by Essence Parent has expired, removing a significant regulatory closing condition. This follows the definitive agreement announced on May 1st for Esperion to be acquired for $3.16 per share, and prior German antitrust clearance on June 9th. The HSR expiration is a critical step, increasing the certainty of the acquisition closing. Stockholder approval is the next major hurdle, with a virtual special meeting scheduled for July 8th.
At the time of this announcement, ESPR was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $814.3M. The 52-week trading range was $0.95 to $4.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.